Fatty Acid Binding Protein 4 Could Be a Linking Biomarker Between Periodontitis and Systemic Diseases

<b>Background/Objectives</b>: This study aims to investigate the relationship between serum fatty acid-binding protein 4 (FABP4) levels and the severity of periodontitis in systemically healthy individuals. Additionally, the study examines whether non-surgical periodontal treatment can reduce FABP4 levels, establishing its potential as a biomarker linking periodontitis to systemic diseases. <b>Methods</b>: A total of 89 participants with stage I, II, or III periodontitis were recruited, excluding individuals with systemic diseases. Clinical parameters such as clinical attachment level (CAL), probing depth (PD), and gingival index (GI) were recorded. Serum FABP4 levels and <i>Porphyromonas gingivalis</i> (<i>P. gingivalis</i>) antibody titers were measured before and after periodontal treatment using ELISA kits. Statistical analysis included <i>t</i>-tests, correlation analysis, and multiple linear regression to assess changes in FABP4 levels and their association with clinical parameters. <b>Results</b>: FABP4 and <i>P. gingivalis</i> antibody titers significantly increased with the severity of periodontitis (<i>p</i> < 0.001). After non-surgical periodontal treatment, FABP4 levels significantly decreased across all stages of periodontitis. Moderate positive correlations were observed between FABP4 and CAL, PD, GI, and <i>P. gingivalis</i> antibody titers (<i>p</i> < 0.05). Multiple linear regression showed that FABP4 levels increased significantly with the progression of periodontitis, independent of age and sex. <b>Conclusions</b>: The study indicates that FABP4 is a potential biomarker for linking periodontitis to systemic conditions such as cardiovascular diseases and diabetes. Non-surgical periodontal treatment reduced FABP4 levels, potentially contributing to the improvement of systemic conditions associated with elevated FABP4. Further research should explore the role of FABP4 in patients with periodontitis and systemic diseases to strengthen its clinical relevance.